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Prof. Laurence Egan, MD 
Editor in Chief 
Journal of Crohn’s and Colitis 
 
Prof. Shomron Ben-Horin, MD 
Associate Editor 
 
Dear Editor in Chief, 
Dear Associate Editor, 
 
Please find attached the revised version of our manuscript:  
 
Article title: “Prediction of short- and medium-term efficacy of biosimilar infliximab 
therapy. Do trough levels/antidrug antibody levels or clinical/biochemical markers play 
a more important role?” 
 
Authors: 1Lorant Gonczi, 1Zsuzsanna Vegh, 1Petra Anna Golovics, 2 Mariann Rutka, 
1Krisztina Barbara Gecse, 2Renata Bor, 2Klaudia Farkas, 3Tamás Szamosi,  4László Bene, 
5Beáta Gasztonyi, , 6Tünde Kristóf, , 7László Lakatos,  8Pál Miheller, 9Károly Palatka, 9Mária 
Papp, 10Árpád Patai, 11Ágnes Salamon, 12Gábor Tamás Tóth, 13Áron Vincze, 14Edina Biro, 
1Barbara Dorottya Lovasz, 1Zsuzsanna Kurti, 2Zoltan Szepes, 2Tamás Molnár, 1Péter L. 
Lakatos 
 
We thank the reviewers and associate editor for the detailed and helpful comments that helped 
in further clarifying the manuscript. 
 
We are sending revised version as requested to the editorial office: in red the new text (and 
NOT SHOWING the text that was removed): 
 
 
 
 
Associate Editor’s comment: 
 
Please consider to include in the manuscript itself the results you reported in the 
response letter, namely that "Week 14 or 30 drug cut-off levels were not associated with 
clinical outcomes at week 30 or 54 in a ROC analysis (AUC 0.47-0.60)". This is 
importatnt as it stands in contrast to Cornille et al findings reported in Gut 2014 (Ref 
35), and is especially pertinent since you devoted a full paragraph in page 21 to discuss 
Cornille publication. Your findings are thus important message for clinicains to 
understand that w14 levels can not still be taken as holy grail to predict long term 
outcomes, so I think these week 14 drug levels analyses (for UC and CD) should be 
included in the manuscript Results section, and referred to in the Discussion when you 
discuss Cornille paper. 
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Thank you for the comment. We included these results and revised the Discussion in our 
manuscript as suggested. 
 
 
 
 
 
 
 
Sincerely yours, 
 
Lóránt Gönczi, MD 
1st Department of Medicine 
Semmelweis University 
Koranyi str. 2/A, Budapest, H-1083 Hungary 
Tel: +36 308208250 
e-mail: lorantgonczi@gmail.com 
 
 
Peter L. Lakatos, MD, PhD    
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Semmelweis University     
Koranyi str. 2/A, Budapest, H-1083 Hungary   
Tel: +36-1-210-0278 / 1500, 1520    
Fax: +36-1-313-0250      
e-mail: lakatos.peter_laszlo@med.semmelweis-univ.hu  
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ABSTRACT 
Background and Aims: Biosimilar infliximab CT-P13 received European Medicines Agency 
(EMA) approval in June 2013 for all indications of the originator product. In the present study 
we aimed to evaluate the predictors of short- and medium-term clinical outcome in patients 
treated with the biosimilar infliximab at the participating IBD centres in Hungary.  
 
Methods: Demographic data were collected and a harmonized monitoring strategy was 
applied. Clinical and biochemical activity were evaluated at weeks 14, 30 and 54. Trough 
level (TL) and anti-drug antibody (ADA) concentration were measured by ELISA (LT-005, 
Theradiag, France) at baseline at 14, 30 and 54 weeks and in 2 centres at weeks 2 and 6. 
 
Results: 291 consecutive IBD patients (184 CD/107 UC) were included. In UC, TLs at week 
2 were predicting both clinical response and remission at week 14 and 30 (clinical 
response/remission at week 14: AUC=0.81, p<0.001, cut-off: 11.5µg/ml/AUC=0.79, p<0.001, 
cut-off: 15.3µg/ml; clinical response/remission at week 30: AUC=0.79, p=0.002, cut-off:11.5 
µg/ml/AUC=0.74, p=0.006, cut-off: 14.5µg/ml), while ADA positivity at week 14 was 
inversely associated with clinical response at week 30 (58.3%vs.84.8%,p=0.04). Previous 
anti-TNF exposure was inversely associated with short-term clinical remission (week 2: 
18.8% vs. 47.8%, p=0.03, at week 6: 38.9% vs. 69.7%, p=0.013, at week 14: 37.5% vs. 2.5%, 
p=0.06). In CD, TLs at week 2 were predicting short term- (week 14 response/remission, 
AUCTLweek2=0.715/0.721, p=0.05/0.005) but not medium-term clinical efficacy. In addition, 
early ADA status by week 14 (p=0.04-0.05 for week 14 and 30), early clinical response 
(p<0.001 for week 30/54) and normal CRP at week 14 (p=0.005-0.0001) and previous anti-
TNF exposure (p=0.03-0.0001 for week 14, 30 and 54) were associated with short-and 
medium-term clinical response and remission. 
Page 6 of 45
https://mc.manuscriptcentral.com/ecco-jcc
Manuscripts submitted to Journal of Crohn's and Colitis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
 4
 
Conclusions: In UC, early TLs were predictive for short-and medium term clinical efficacy, 
while in CD, week 2 TLs were associated only with short-term clinical outcomes. 
 
Key words: biosimilar infliximab, inflammatory bowel diseases 
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Introduction 
Biosimilar infliximab CT-P13 was approved by the European Medicines Agency (EMA) in 
2013 and by the Food and Drug Administration (FDA) in 2016 for the use in all indications of 
the originator infliximab1,2. The use of biosimilar infliximab is mandatory in Hungary since 
May 2014 in all new inflammatory bowel disease (IBD) patients, including anti-TNF naïve 
patients and in patients who were previously successfully treated with the originator product 
but were on drug holiday for at least 12 months. Data on the efficacy, safety and 
immunogenicity of the biosimilar IFX in IBD from real-life cohort studies published so far 
showed comparable outcomes to those of the originator product3,4,5,6,7,8,9,10,11,12,13,14. 
The efficacy of anti-TNF therapy in Crohn’s disease (CD) has been reported to be 
associated with shorter disease duration, isolated colonic disease location, absence of previous 
surgery, young age and non-smoking status15. High C-reactive protein (CRP) level (≥0.8 
mg/dl) at start of the infliximab (IFX) therapy was associated with corticosteroid-free clinical 
remission at week 26 in CD patients16. 
In the study by García-Bosch et al., higher albumin level was predicitve of clinical 
remission at week 8 (OR 1.4, CI 95 % 1.06–1.8; p= 0.017), while clinical remission at week 8 
was the only independent predictor for maintained clinical remission at week 30 and 54 in 
ulcerative colitis (UC) patients treated with IFX. Previous cyclosporine therapy, absence of 
concomitant immunomodulator and absence of response at week 8 were associated with a 
higher colectomy rate at week 5417. 
The use of therapeutic drug monitoring (TDM) has become widespread in 
management of patients receiving biological therapy. CD patients with loss of response 
(LOR) to infliximab had significantly lower IFX trough levels (TLs) and higher anti-drug 
antibody (ADA) levels compared to responders (cut-off values for identifying LOR: <0.5 
µg/ml for IFX TL and ≥10 U/ml for ADA)18.The rate of clinical remission was higher in CD 
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patients with detectable IFX TLs compared to patients with undetectable serum IFX TLs after 
a median of 14 infusions (82% vs. 6%; p<0.001)19. In the TAXIT (Trough level Adapted 
infliXImab Treatment) trial IBD patients were assigned to groups either receiving infliximab 
based on their clinical activity or based on their TL after reaching the target infliximab 
concentration (3-7 µg/mL). No significant difference was found between the TDM-based 
strategy and clinically-based dosing in achieving clinical remission after one year. However, 
TDM-based dosing was associated with fewer flares during follow-up20. According to the 
findings of the Tailored Treatment With Infliximab for Active Crohn's Disease (TAILORIX) 
study, trough-level-based and symptom-driven dose adaptation did not differ in terms of the 
proportion of CD patients being in steroid-free clinical remission from week 22 to 54 and in 
endoscopic remission at week 5421.  
Until now, few data are available on the predictive potential of the IFX TL and ADA 
status in IBD patients treated with IFX. In a post-hoc analysis of a multicenter, prospective 
trial with the originator IFX, TLs at week 2 were significantly associated with week 14 and 30 
clinical remission and mucosal healing at week 30 in UC22.  
Therefore, in the present study we aimed to prospectively identify the predictors of 
short- and medium-term clinical outcome in patients treated with the biosimilar infliximab 
CT-P13 in a nationwide cohort of IBD patients. In addition to clinical factors, the predictive 
potential of biochemical markers and serial TDM samples were also evaluated. 
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Materials and Methods 
The inclusion period of this prospective, nationwide, multicenter, observational study started 
in May 2014 at 12 IBD centres in Hungary. Unselected, consecutive IBD patients starting on 
biosimilar infliximab were prospectively enrolled. No patient received originator infliximab 
12 months prior to the initiation of biosimilar infliximab therapy. A harmonized monitoring 
strategy was applied as requested by the Hungarian National Health Fund (Table 1). Clinical 
(Crohn’s Disease Activity Index (CDAI) in CD and partial Mayo Score (pMayo) in UC) and 
biochemical activity (including total blood count [TBC], serum C-reactive protein [CRP, 
normal cut-off: 5 mg/l], and albumin) were evaluated at baseline and at weeks 14, 30 and 54.  
Disease location and disease behaviour in CD and disease extent in UC were classified 
according to the Montreal classification23. 
In CD, clinical remission was defined as a CDAI < 150 points or no fistula drainage as 
assessed by the Fistula Drainage Assessment, while clinical response was defined as a 
decrease in CDAI with more than 70 points or at least 50% reduction in the number of 
draining fistulas24,25. In UC, clinical remission was defined as a pMayo of less than 3 points 
and clinical response was defined as a decrease in the pMayo score with more than 3 points26. 
At Week 14, response was evaluated, which qualified patients for maintenance treatment.  
Biosimilar IFX TLs and ADA levels were measured using the conventional and 
bridging enzyme-linked immunosorbent assay [ELISA, [LISA TRACKER, Theradiag, 
France]] at baseline, at weeks 14, 30 and 54 in all participating centres and additionally at 
weeks 2 and 6 in two centres (First Department of Medicine, Semmelweis University, 
Budapest and First Department of Medicine, University of Szeged, Szeged. The ELISA kit 
was validated for accuracy and reproducibility of TDM of the biosimilar IFX [Theradiag, 
France/Hospira, UK]. ELISA measurements were performed at the Department of Laboratory 
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Medicine, Semmelweis University, Budapest. A more detailed description of the case 
ascertainment and monitoring strategy of the present cohort was published earlier6. The 
detection cut-off value of biosimilar infliximab TL was 0.1 µg/ml, while 3-7 µg/ml was 
defined as therapeutic. At week 2 and 6, cut-off values of biosimilar infliximab TL were 
calculated by ROC analysis. The standard cut-off value of ADA level was 10 ng/ml. The cut-
off value of CRP was 10 mg/l. Due to cohort size the predictive potential of clinical and 
biochemical factors at week 54 were calculated in CD, but not in UC.  
 
Statistical considerations 
For categorical data frequency distributions were performed, for continuous variables medians 
and interquartile ranges were calculated. Receiver operating characteristics (ROC) analysis 
was performed to identify cut-off values of TL at week 2 and 6 to identify patients in clinical 
response or remission at week 14, 30 and 54. Chi-squared test was used to evaluate 
differences within subgroups of patients with CD and UC. Sensitivity, specificity, positive 
predictive values (PPV), negative predictive values (NPV) of week 2 TL values were 
calculated. Logistic regression analysis was used to test the association between disease 
characteristics, clinical and biochemical factors and clinical response or remission at week 2, 
6, 14, 30 and 54, independent variables with a p value of <0.1 were selected for multivariate 
analysis. A p value of < 0.05 was considered as significant. Statistical analysis was performed 
using SPSS software v. 20.0 (Chicago, IL). 
Ethical statement 
Ethical approval was acquired from the National Ethical Committee 929772-2/2014/EKU 
[292/2014]). The study was registered at the EMA European Network of Centres for 
Pharmacoepidemiology and Pharmacovigilance [ENCEPP/SDPP/9053]. Written informed 
consent was signed by all participants.  
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Results 
A total of 291 consecutive IBD patients - 184 patients with CD and 107 patients with UC - 
were enrolled in the study. Patient characteristics are shown in Table 2. Mean TLs were 20.1, 
14.7 and 5.1 µg/ml at weeks 2, 6 and 14 (n=124, 86 and 158). Cumulative ADA positivity 
rates were 8.7%, 19.3%, and 28.0% in IBD patients at weeks 0, 14, and 30 (ntotal= 229, 192 
and 143).  
 
Ulcerative colitis 
Association between early trough levels and ADA status and clinical outcomes 
TLs measured at week 2 in UC were predictive for both clinical response and remission at 
week 14 and 30 (clinical response at week 14: AUC=0.81, p<0.001, cut-off: 11.5 µg/ml, 
clinical remission at week 14: AUC=0.79, p<0.001, cut-off: 15.3 µg/ml; clinical response at 
week 30: AUC=0.79, p=0.002, cut-off: 11.5 µg/ml, clinical remission at week 30: AUC=0.74, 
p=0.006, cut-off: 14.5 µg/ml) (Figure 1A, 1B, 2A, 2B). Sensitivity, specificity, PPV, NPV 
were also calculated. (Table 3.) 
 
TLs measured at week 6 were not associated with either clinical response or remission at 
week 14 or 30 (clinical response at week 14: AUC: 0.62, p=0.40, clinical remission at week 
14: AUC: 0.63, p=0.19, clinical response at week 30: AUC: 0.76, p=0.08, AUC: 0.68, 
p=0.12). TLs measured at week 14 or 30 were also not associated with clinical outcomes at 
week 30 or 54 in a ROC analysis (AUC: 0,47-0,60). 
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Cumulative ADA development at week 14 was inversely associated with clinical response at 
week 30 (58.3% vs. 84.8%, p=0.04, OR: 0.25, 95%CI: 0.06-1.02), but not with clinical 
response and remission at week 14 (75% vs. 88.7%, p=0.16, OR: 0.38, 95%CI: 0.10-1.52; 
62.5% vs. 66.1%, p=0.79, OR: 0.85, 95%CI: 0.27-2.67) and clinical remission at week 30 
(41.7% vs. 56.5%, p=0.36, OR: 0.55, 95%CI: 0.15-1.99). Concomitant steroid or AZA 
therapy was not associated with ADA positivity at week 2, 6, 14 and 30. 
 
Predictive potential of clinical and biochemical factors 
Previous anti-TNF exposure was inversely associated with clinical remission at week 2 
(18.8% vs. 47.8%, p=0.03, OR: 3.97, 95%CI: 1.06-14.92), at week 6 (38.9% vs. 69.7%, 
p=0.013, OR: 0.28, 95%CI: 0.097-0.792), but not with clinical response at week 2 and week 6 
(week 2: 43.8% vs. 59.3%, p=0.245, OR: 0.53, 95%CI: 0.18-1.56; week 6: 61.1% vs. 74.4%, 
p=0.252, OR: 0.54, 95%CI: 0.19-1.57) and there was a tendency for association with clinical 
remission at week 14 (p=0.06). No association was found between previous anti-TNF 
exposure and clinical response or remission at week 30 (p=0.12 and p=0.11). Previous anti-
TNF exposure was associated with ADA development at week 0, 2 and 6 (p<0.001, p<0.001 
and p=0.012), but was not associated with cumulative ADA development at week 14 and 30 
(p=0.192, OR: 0.552, 95%CI: 0.235-1.30 and p=0.38, OR: 0.69, 95%CI: 0.31-1.53).  Gender, 
disease extent, concomitant steroid or AZA therapy were not associated with clinical response 
or remission at weeks 2, 6, 14 and 30 (Tables 4 and 5).  
 
Crohn’s disease 
Association between early trough levels and ADA status and clinical outcomes 
Trough levels measured at week 2 in CD were associated both with clinical response and 
remission at week 14 (Figure 3A and 3B).  
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Trough levels measured at week 6 were not predictive for the clinical efficacy at weeks 14, 30 
and 54 (clinical response at week 14: AUC=0.47, p=0.8, clinical remission at week 14: 
AUC=0.6, p=0.22, clinical response at week 30: AUC=0.5, p=0.98, clinical remission at week 
30: AUC=0.6, p=0.31, clinical response at week 54: AUC=0.51, p=0.97, clinical remission at 
week 54: AUC=0.45, p=0.69). Week 14 or 30 cut-off levels were also not associated with 
clinical outcomes at week 30 or 54 (AUC: 0.50-0.54). 
 
ADA positivity was inversely associated with clinical remission at week 14 (48.5% vs. 
66.9%, p=0.04, OR: 2.15, 95%CI: 0.996-4.63), but not with clinical response at week 14 
(81.8% vs. 90.6%, p=0.15, OR: 0.46, 95%CI: 0.16-1.33), clinical response and remission at 
week 30 and 54 (clinical response at week 30: 69.2% vs. 85.3%, p=0.054, OR: 0.39, 95%CI: 
0.14-1.04, clinical remission at week 30: 46.2% vs. 64.2%, p=0.09, OR: 0.48, 95%CI: 0.20-
1.13, clinical response at week 54: 59.1% vs. 75.5%, p=0.16, OR: 0.47, 95%CI: 0.16-1.35, 
clinical remission at week 54: 45.5% vs. 60.4%, p=0.24, OR: 0.55, 95%CI: 0.2-1.49) 
 
Predictive potential of clinical and biochemical factors 
Normal CRP level at week 14 was associated with clinical response and remission at week 14 
(p<0.001 and p<0.001) and at week 30 (p<0.001 and p=0.005) but not with clinical response 
and remission at week 54 (p=0.10 and p=0.114). Previous anti-TNF exposure was inversely 
associated with clinical response and remission at week 14 (p=0.002 and p=0.002), clinical 
response and remission at week 30 (p=0.008 and p=0.03) and at week 54 (p<0.001 and 
p=0.004). Previous anti-TNF exposure was associated with ADA development at week 0 and 
2 (p<0.001 for both), but not at weeks 6, 14 or 30. Clinical response at week 14 was 
associated with clinical response and remission at week 30 (p<0.001 and p<0.001) and at 
week 54 (p<0.001 and p<0.001). Clinical remission at week 14 was associated with clinical 
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response and remission at week 30 (p<0.001 and p<0.001) and with clinical response and 
remission at week 54 (p<0.001 and p<0.001). Gender, disease location, disease behaviour, 
perianal disease, previous or concomitant steroid or AZA therapy was not associated with 
clinical response or remission at weeks 14, 30 and 54 (Tables 4, 5 and 6). Normal CRP and 
clinical response or remission at week 14 but not previous anti-TNF exposure was 
significantly associated with clinical response or remission rates at week 30 or 54 in 
multivariate analysis. Of note, previous anti-TNF exposure can not be assumed to be 
independent from week 14 clinical utcomes.   
Discussion 
This is the first report on the predictive value of TL levels and ADA status in IBD patients 
treated with biosimilar infliximab in a prospective, nationwide, multicentre IBD cohort. In 
UC, TLs measured at week 2 were associated with clinical response and remission at both 
week 14 and 30, while ADA development at week 14 was inversely associated with clinical 
response at week 30.  
These results are in agreement with previous observations in UC patients treated with 
the originator IFX therapy, where TL ≥ 20.7 ug/l at week 2 was significantly associated with 
clinical remission week 14 and 30 22. A retrospective study from a tertiary referral center 
investigated the association between early TLs and short-term mucosal healing (STMH) at 
week 14. Patients with STMH had higher TLs at week 2, 6 and 14 compared to patients 
without STMH (ROC curve analysis: infliximab concentration thresholds of 28.3, 15.0, and 
2.1 mg/mL)27.  
In a study involving 115 UC patients treated with IFX over a median period of 13.9 
months, patients with detectable IFX TL had higher rates of clinical remission (69% vs. 15%; 
p<0.001), endoscopic improvement (76% vs. 28%; p<0.001), endoscopic remission (27% vs. 
8%; p=0.021) and a lower rate of colectomy (7% vs. 55%; p<0.001) compared to patients 
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with undetectable serum IFX TL. Univariate analysis identified baseline Mayo score ≥10, 
antibodies to IFX and detectable IFX TL as predictors for clinical remission and colectomy 
(clinical remission: Mayo score≥10: OR: 0.36 (95%CI: 0.15-0.83) p=0.028, antibodies to 
IFX: OR: 0.15 (95%CI: 0.06-0.40) p<0.001, detectable IFX level: OR: 12.0 (95%CI: 4.76-
30.26) p<0.001; colectomy: Mayo score≥10: OR: 3.42 (95%CI: 1.56-7.51) p=0.004, 
antibodies to IFX: OR: 2.71 (95% CI: 1.22-6.01), p=0.023, detectable IFX TL: OR: 0.13 
(95%CI: 0.05-0.35) p<0.001). In addition, undetectable IFX TL was a strong predictor for the 
need for colectomy (OR 9.3, 95%CI: 2.9-29.9; p<0.001)28. According to the results of the 
post-hoc analysis of the ACT-1 and ACT-2 (Active Ulverative Colitis Trials) trials, serum 
IFX levels at weeks 8, 30 and 54 were significantly in higher in UC patients being in clinical 
response and/or remission or having mucosal healing compared to patients having lower IFX 
levels. Furthermore, patients with lower IFX levels were more likely to fail to maintain 
clinical efficacy compared to patients with higher IFX levels.29  
In CD, week 2 TL was associated and ADA positivity was inversely associated with 
clinical remission at week 14. In contrast, TDM was not predicting medium-and long-term 
clinical efficacy. Other studies investigated the association of TL and ADA status of 
originator IFX with clinical outcomes. In the study by Maser et al., out of 105 CD patients 90 
patients continued maintenance scheduled IFX treatment with a median follow-up of 23 
months. The rate of clinical remission was higher in CD patients with detectable IFX TL 
(82% vs. 6%; p<0.001). In addition, detectable IFX TL was associated with lower CRP level 
(2.0 vs 11.8 mug/L; p< 0.001) and endoscopic improvement (88% vs 33%; p< 0.001)30. In a 
study with 125 consecutive CD patients starting IFX therapy, antibody concentration of ≥8.0 
µg/ml was a predictive factor of a shorter duration of clinical response. The median duration 
of clinical response in patients with antibody concentrations ≤ 8.0 µg/ml was 71 days (95%CI: 
57-88) compared to 35 days (95%CI: 28-42) in the group of patients with antibody 
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concentrations of ≥8.0 µg/ml (p<0.001). Antibodies against IFX were independently 
associated (p<0.001), whereas the use of immunosuppressive agents (p=0.58) and the 
infliximab concentrations (p=0.70) were not associated with shorter duration of clinical 
response in logistic-regression analysis31. 
In CD, normal CRP level at week 14 was associated with clinical remission at week 14 
and at week 30. CRP is an accurate marker strongly correlating with disease activity and 
endoscopic inflammation in patients with CD32,33. High-sensitivity CRP (hs-CRP) positivity 
at diagnosis might be a helpful marker also for patient classification, as it was associated with 
colonic and ileocolonic disease location, non-inflammatory disease behaviour and with the 
need for azathioprine or biological therapy during the later disease course. In addition, in 
patients having elevated hs-CRP level at diagnosis, hs-CRP was an independent predictor for 
clinical relapse at 3 and 12 month 34. In the post-hoc analysis of A Crohn's Disease Clinical 
Trial Evaluating Infliximab in a New Long-term Treatment Regimen I (ACCENT I) trial, 
week 14 IFX TL with a cut-off point of ≥3.5 mg/mL and a CRP decrease ≥ 60% from 
baseline at week 14 (OR: 3.5, 95% CI: 1.1-11.4 and OR: 7.3, 95%CI: 1.4-36.7) were 
predictive factors for long-term sustained clinical response in CD patients with elevated 
baseline CRP level (>8.0 mg/L) given infliximab 5 mg/kg every 8 weeks. In contrast, in our 
study TLs measured at week 14 were not associated with medium-, long term (week 30 and 
week 54) clinical outcomes35. In another post-hoc analysis of the ACCENT I trial high 
baseline CRP level (cut- off points of 0.7– 2.5 mg/ dL) was associated with maintenance of 
clinical remission through 54 weeks of IFX therapy. Normal week-14 CRP levels with cut-off 
points of 0.5, 0.6, 0.7 and 0.9-mg/ dl were significantly associated with maintained clinical 
response, while the absolute reduction of CRP level between baseline and week 14 was 
significantly associated with the maintenance of clinical response and remission between 
weeks 14 and 5436.  
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We found no association between other investigated clinical factors, as gender, disease 
behaviour, disease extent, concomitant steroid/azathioprine therapy and the clinical outcomes 
in IBD patients on biosimilar infliximab therapy. Similarly, Seow et al. reported no effect of 
concurrent immunosuppressive therapy on clinical remission and colectomy rates in a cohort 
of 115 UC patients on IFX therapy28. In contrast, in the study by Papamichael et al., 
univariate analysis identified female gender (p=0.039), concomitant immunomodulators at 
start of infliximab (p=0.028) as variables associated with short-term mucosal healing in UC 
patients27. Of note, previous anti-TNF exposure was inversely associated with clinical 
remission at week 14, 30 and 54 in CD, while in UC, previous anti-TNF exposure was only 
associated with short-term clinical outcomes. In the previous study of our study group 
enrolling 210 IBD patients on biosimilar infliximab therapy, clinical remission rates were also 
influenced by previous exposure to the originator infliximab both in CD and UC at week 14 
but not at week 30 (at week 14 clinical remission with no previous exposure vs. previous 
exposure to the originator infliximab: CD: 60.9% vs. 35.7% p<0.05, UC: 65.1% vs. 33.3%, 
p<0.05 and p<0.05, at week 30: CD: 60% vs. 38.9%, p=0.13, UC: 78.9% vs. 33.3%, p=0.06)6.  
The main strengths of the present study are the prospective data collection and the 
standardized, harmonized monitoring strategy. So far, the predictive value of TL and ADA 
level in IBD patients receiving biosimilar infliximab therapy was not studied. Limitations of 
our study are that TDM measurement at week 2 and 6 was not mandatory, only selected 
centres participated. Furthermore, endoscopic evaluation was not performed at weeks 14 or 30 
and predictive potential was evaluated compared to clinical and biochemical remission 
criteria. Of note, the assay was not able to detect ADA in the presence of drug, which may 
have influenced the ADA clinical outcome associations as suggested in recent publications.37 
In conclusion, TL measured at week 2 might be an important factor in the prediction of 
short-and medium-term clinical efficacy in UC and short-term clinical outcomes in CD 
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patients treated with biosimilar infliximab. Further prospective studies are needed to 
determine the role of TDM in the prognosis of the clinical efficacy of biosimilar infliximab 
therapy. In addition, previous anti-TNF exposure has been proven to be a relevant factor 
associated with clinical efficacy throughout the 54-week treatment period in CD, while it was 
associated only with short-term clinical outcomes in UC.  
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Figure legends 
 
Figure 1A. Predictive power of infliximab trough levels measured at week 2 for 
identifying clinical response at week 14 in patients with ulcerative colitis 
(AUCTLweek2=0.81, p<0.001, cut-off: 11.5 µg/ml) 
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Figure 1B. Predictive power of infliximab trough levels measured at week 2 for 
identifying clinical remission at week 14 in patients with ulcerative colitis 
(AUCTLweek2=0.79, p<0.001, cut-off: 15.3 µg/ml) 
Page 27 of 45
https://mc.manuscriptcentral.com/ecco-jcc
Manuscripts submitted to Journal of Crohn's and Colitis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
 25
                                                                                                                                                                             
Figure 2A. Predictive power of infliximab trough levels measured at week 2 for 
identifying clinical response at week 30 in patients with ulcerative colitis 
(AUCTLweek2=0.79, p=0.002, cut-off: 11.5 µg/ml) 
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Figure 2B. Predictive power of infliximab trough levels measured at week 2 for 
identifying clinical remission at week 30 in patients with ulcerative colitis 
(AUCTLweek2=0.74, p=0.006, cut-off: 14.5 µg/ml) 
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Figure 3A. Predictive power of infliximab trough levels measured at week 2 for 
identifying clinical response at week 14 in patients with Crohn’s disease 
(AUCTLweek2=0.72, p=0.05, 95%CI: 0.496-0.933, cut-off: 16.9µg/ml) 
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Figure 3B. Predictive power of infliximab trough levels measured at week 2 for 
identifying clinical remission at week 14 in patients with Crohn’s disease 
(AUCTLweek2=0.72, p=0.005, 95%CI: 0.575-0.868, cut-off: 20.4 µg/ml) 
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Tables 
Table 1.  Monitoring strategy of Hungarian patients with inflammatory bowel disease 
receiving biosimilar infliximab 
 Baseline Week 14 Week 30 Week 54 
Demographic data ✔     
Medication history ✔  ✔  ✔  ✔  
Clinical activity 
  CDAI/PDAI or pMayoa 
✔  ✔  ✔  ✔  
Biochemical activity 
  WBC, CRP, We, albuminb 
✔  ✔ ✔  ✔  
a CDAI: Crohn’s Disease Activity Index, PDAI:  Perianal Disease Activity Index, pMayo: 
partial Mayo Score, b WBC: white blood cell, CRP: C-reactive protein 
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Table 2. Characteristics of patients with inflammatory bowel disease receiving 
biosimilar infliximab in the participating Hungarian centers 
 Crohn’s disease  
(N = 184) 
Ulcerative colitis 
(N= 107) 
Male/female 82 / 102 62/45 
Age at onset, median (IQR) 23 (19-34) yrs 28 (22-39) yrs 
Disease duration, median 
(IQR) 
5 (2-11) yrs 4 (2-11) yrs 
Baseline disease activity,  
median (IQR) 
CDAI: 321 (301-352) 
n=145 
PDAI: 10 (IQR: 6-11) n=56 
MAYO: 9 (IQR: 7-11) 
n=107 
pMAYO: 7 (IQR: 6-9) 
n=107 
Disease location  
(L1/L2/L3/L4/all L4)a 
16.8%/32.4%/ 
49.1%/1.7%/7.9% 
- 
Disease extent (E1/E2/E3)b - 8.4% / 32.7% / 51.1% 
Disease behavior (B1/B2/B3)c 58.7% / 21.2% / 20.1% - 
Perianal disease 35.0% - 
Previous surgery 22.5% - 
Prior treatments 
5-ASA
d
 84.6% 92.3% 
Steroids 81.0% 90.9% 
AZA
e
 87.4% 74.5% 
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CSA
f
 - 7.3% 
Anti-TNF (IFX/ADA) 24.5% (21.8%/2.7%) 14.0% (9.4%/4.6%) 
Concomitant imunomodulators 
Steroids 44.2% 66.4% 
AZA
e
 60.3% 51.4% 
a
 L1: ileal, L2: colonic, L3: ileocolonic, L4: upper GI disease, b E1: proctitis, E2: left-sided 
colitis, E3: extensive colitis, c B1: non-stricturing, non-penetrating, B2: stricturing, B3: 
penetrating, d 5-ASA: 5-aminosalicylic acid, e AZA: azathioprine, f CSA: cyclosporin A 
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Table 3.  Sensitivity, specificity, positive predictive values (PPV), negative predictive values 
(NPV) of week 2 TL values 
 
 Sensitivity Specificity NPV d PPV e 
CD
a 
week 2 TL
b
 
14 response 
71% 50% 19% 91% 
CD
a
 week 2 TL
b
 
14 remission 
68% 59% 59% 68% 
UC
c
 week 2 TL
b
  
14 response 
79% 80% 57% 92% 
UC
c
 week 2 TL
b
  
14 remission 
72% 76% 68% 80% 
UC
c
 week 2 TL
b
  
30 response 
78% 85% 61% 93% 
UC
c
 week 2 TL
b
 
30 remission 
70% 76% 70% 76% 
a CD: Crohn’s disease, b TL: trough level, c UC: ulcerative colitis, d  NPV: negative predictive 
value, e  PPV: positive predictive value 
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Table 4. Clinical and biochemical factors associated with clinical response and remission 
at week 14 in patients with inflammatory bowel disease on biosimilar infliximab therapy 
 Clinical response at week 14 Clinical remission at week 14 
OR CI (95%) p OR CI (95%) p 
Ulcerative colitis 
Previous anti-TNF exposure 0.77 0.22-2.68 0.68 0.36 0.12-1.08 0.06 
Gender 0.89 0.34-2.29 0.80 0.86 0.39-1.92 0.72 
Disease extent - - 0.37 - - 0.44 
Concomitant steroid therapy 0.77 0.28-2.10 0.60 1.05 0.47-2.36 0.90 
Concomitant AZA therapya 0.66 0.25-1.71 0.39 0.61 0.28-1.34 0.22 
Crohn’s disease 
Normal CRP level at week 14b 5.59 2.21-14.08 <0.001 4.57 2.22-9.43 <0.001 
Previous anti-TNF exposure 3.04 1.48-6.21 0.002 2.74 1.44-5.21 0.002 
Gender 1.28 0.66-2.47 0.46 0.84 0.50-1.40 0.50 
Disease location - - 0.22 - - 0.10 
Disease behavior - - 0.13 - - 0.61 
Perianal disease 1.16 0.42-3.2 0.78 0.85 0.40-1.79 0.66 
Previous steroid therapy 1.65 0.68-3.99 0.27 1.47 0.68-3.18 0.32 
Previous AZA therapya 0.93 0.38-2.27 0.87 0.75 0.37-1.52 0.43 
Concomitant steroid therapy - - 0.84 - - 0.60 
Concomitant AZA therapya 1.15 0.59-2.24 0.68 0.80 0.47-1.36 0.41 
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a AZA: azathioprine, b CRP: C-reactive protein 
 
 
 
Table 5. Clinical and biochemical factors associated with clinical response and remission 
at week 30 in patients with inflammatory bowel disease on biosimilar infliximab therapy 
 Clinical response at week 30 Clinical remission at week 30 
OR CI (95%) p OR CI (95%) p 
Ulcerative colitis 
Previous anti-TNF exposure 0.38 0.11-1.33 0.12 0.33 0.08-1.35 0.11 
Gender 0.84 0.31-2.28 0.73 1.05 0.41-2.67 0.92 
Disease extent - - 0.99 - - 0.26 
Concomitant steroid therapy 0.99 0.36-2.73 0.99 0.68 0.27-1.74 0.42 
Concomitant AZA therapya 0.80 0.30-2.15 0.66 0.53 0.21-1.33 0.17 
Crohn’s disease 
Normal CRP level at week 14b 7.81 3.07-20 <0.001 3.16 1.38-7.30 0.005 
Previous anti-TNF exposure 2.7 1.28-5.71 0.008 2.21 1.07-4.57 0.03 
Clinical response at week 14 42.81 15.20-120.54 <0.001 21.41 6.23-73.57 <0.001 
Clinical remission at week 14 9.84 4.19-23.11 <0.001 9.41 4.64-19.08 <0.001 
Gender 0.72 0.36-1.41 0.33 0.80 0.44-1.46 0.47 
Disease location - - 0.49 - - 0.03 
Disease behavior - - 0.12 - - 0.21 
Perianal disease 0.57 0.22-1.52 0.26 0.54 0.23-1.27 0.16 
Previous steroid therapy 0.66 0.17-2.55 0.54 0.75 0.32-1.80 0.52 
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Previous AZA therapya 0.95 0.39-2.31 0.91 1.05 0.48-2.28 0.90 
Concomitant steroid therapy 1.07 0.55-2.10 0.84 0.86 0.47-1.56 0.62 
Concomitant AZA therapya 1.22 0.61-2.42 0.58 1.13 0.61-2.08 0.70 
a AZA: azathioprine, b CRP: C-reactive protein 
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Table 6. Clinical and biochemical factors associated with clinical response and remission 
at week 54 in patients with Crohn’s disease on biosimilar infliximab therapy 
 Clinical response at week 54 Clinical remission at week 54 
OR CI (95%) p OR CI (95%) p 
Crohn’s disease 
Normal CRP level at week 14a 0.42 0.14-1.20 0.10 0.45 0.16-1.23 0.11 
Previous anti-TNF exposure 6.25 2.21-17.54 <0.001 4.57 1.54-13.51 0.004 
Clinical response at week 14 15.25 4.94-47.14 <0.001 7.39 2.48-21.98 <0.001 
Clinical remission at week 14 11.13 4.14-29.91 <0.001 4.61 1.93-11.05 <0.001 
Gender 0.72 0.31-1.66 0.44 0.55 0.24-1.26 0.16 
Disease location - - 0.30 - - 0.31 
Disease behavior - - 0.19 - - 0.23 
Perianal disease 0.62 0.20-1.88 0.39 0.88 0.29-2.67 0.82 
Previous steroid therapy 1.29 0.47-3.54 0.62 1.31 0.47-3.60 0.60 
Previous AZA therapyb 0.34 0.10-1.12 0.07 0.51 0.18-1.45 0.20 
Concomitant steroid therapy 1.29 0.58-2.88 0.54 0.85 0.38-1.88 0.69 
Concomitant AZA therapyb 0.85 0.37-1.96 0.70 1.02 0.45-2.31 0.97 
a CRP: C-reactive protein, b AZA: azathioprine 
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Predictive power of infliximab trough levels measured at week 2 for identifying clinical response at week 14 
in patients with ulcerative colitis (AUCTLweek2=0.81, p<0.001, cut-off: 11.5 µg/ml)  
Figure 1A  
423x339mm (300 x 300 DPI)  
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Predictive power of infliximab trough levels measured at week 2 for identifying clinical remission at week 14 
in patients with ulcerative colitis (AUCTLweek2=0.79, p<0.001, cut-off: 15.3 µg/ml)  
Figure 1B  
481x509mm (300 x 300 DPI)  
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Predictive power of infliximab trough levels measured at week 2 for identifying clinical response at week 30 
in patients with ulcerative colitis (AUCTLweek2=0.79, p=0.002, cut-off: 11.5 µg/ml)  
Figure 2A  
560x509mm (300 x 300 DPI)  
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Predictive power of infliximab trough levels measured at week 2 for identifying clinical remission at week 30 
in patients with ulcerative colitis (AUCTLweek2=0.74, p=0.006, cut-off: 14.5 µg/ml)  
Figure 2B  
546x509mm (300 x 300 DPI)  
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Predictive power of infliximab trough levels measured at week 2 for identifying clinical response at week 14 
in patients with Crohn’s disease (AUCTLweek2=0.72, p=0.05, 95%CI: 0.496-0.933, cut-off: 16.9µg/ml)  
Figure 3A  
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Predictive power of infliximab trough levels measured at week 2 for identifying clinical remission at week 14 
in patients with Crohn’s disease (AUCTLweek2=0.72, p=0.005, 95%CI: 0.575-0.868, cut-off: 20.4 µg/ml)  
Figure 3B  
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